HOME >> MEDICINE >> NEWS
Combined contrast enhanced MRI shows promise

Combined contrast enhanced (CCE) MRI, in which two contrast agents are used together, permits accurate non-invasive staging of liver fibrosis in non-alcoholic fatty liver disease (NAFLD), according to a new study by researchers from the University of California, San Diego.

For the study, the researchers reviewed 26 patients with NAFLD who underwent CCE MRI. Using a five-point scale, the researchers found that the staging of the NAFLD on CCE MRI closely matched the staging of NAFLD using conventional pathology.

According to the researchers, the prevalence of NAFLD is increasing in western nations and is a major health problem affecting both children and adults. It is a common cause of cirrhosis in American adults and the most common cause in children.

The definitive method of diagnosis and staging is liver biopsy, but it has several limitations, say the researchers. It is invasive, costly, has risks and only samples about 1/50,000th of the liver. "This sampling issue is important because the pathological processes that affect the NAFLD liver are not evenly distributed throughout, so that tiny changes in needle placement will result in potentially large changes in biopsy interpretation. Because of these limitations, alternative methods such as CCE MR need to be developed," said Claude Sirlin, MD, lead author of the study.

"Except for CCE MR, all other experimental techniques rely on surrogate or indirect markers of fibrosis. CCE MR attempts to directly visualize fibrosis by using two contrast agents with complementary mechanisms, iron particles to darken the background liver and gadolinium to brighten the fibrosis," said Dr. Sirlin, "Gadolinium alone and iron particles alone are not adequate for visualization of fibrosis, unless the fibrosis is extremely advanced. However, when given together, the agents show fibrosis with high clarity," he added.

The combined use of two or more complementary contrast agents is uncommon in r
'"/>

Contact: Necoya Lightsey
necoya@arrs.org
604-647-7413
American Roentgen Ray Society
1-May-2006


Page: 1 2

Related medicine news :

1. Combined molecular-targeted and hormonal therapies offer promise in treating ovarian cancer
2. Combined imaging approach may provide better identification of difficult-to-diagnose brain clots
3. Combined therapies may boost immune response and long-term protection against brain tumors
4. Combined liver-kidney transplant beneficial for patients with dual organ disease
5. Combined treatment cuts inflammatory cells in chronic obstructive pulmonary disease
6. Combined MRI and mammography more effective at detecting breast cancer in high-risk women
7. Fluorescence diffuse optical tomography provides high contrast, 3-D look at breast cancer
8. MRI contrast agent can detect heart attack in the making
9. High-resolution imaging with contrast agent shows promise in osteoarthritis research
10. Using contrast enhanced sonography improves diagnosis of liver and spleen injuries
11. Reducing contrast material injection in elderly patients can lower cost of exam and risks

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Combined contrast enhanced MRI shows promise

(Date:3/29/2015)... The Claudia Cohen Research Foundation and ... that Dr. Beth Y. Karlan has been selected as ... Prize for Outstanding Gynecologic Researcher. The $50,000 prize is ... Annual Meeting on Women's Cancer in Chicago. , Dr. ... at the Samuel Oschin Comprehensive Cancer Institute and Director ...
(Date:3/29/2015)... 2015 Final Cut Pro X ... Pixel Film Studios, entitled TranSports. , “TranSports is ... Final Cut Pro X,” said Christiana Austin, CEO of ... needed to effortlessly transition using this cool sports transition ... and uniquely styled transition pack for Final Cut Pro ...
(Date:3/28/2015)... 2015 Could genetic code determine someone’s ... study by researchers at the Harvard T.H. Chan ... support of the Coffee and Caffeine Genetics Consortium and ... past fall, the study—one of several recent HSPH investigations ... from more than 120,000 regular coffee drinkers of European ...
(Date:3/28/2015)... The California-based leading wig brand UniWigs has prepared a ... during the Easter Holidays from today until April 6th. ... Fools’ Day. , As the winter fades and spring ... Festival, with religious origins to countries in Europe and ... The best wig provider, UniWigs, would like to offer ...
(Date:3/28/2015)... Pitching speed, player’s height, and pitching for multiple ... injuries, according to new research released today at the American ... , “Our findings indicate that a 10 inch increase in ... a history of injury, a 10 mile per hour increase ... a history of injury, and playing for more than one ...
Breaking Medicine News(10 mins):Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 3Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 4Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2
(Date:3/27/2015)... 27, 2015 As of February, InControl ... devices for women. "Shipping thousands of ... part is the hundreds of letters, emails and ... have been positively impacted by our technology," said ... InControl recently released Apex, an over-the-counter solution ...
(Date:3/27/2015)... , March 27, 2015  RXi Pharmaceuticals ... MirImmune LLC, today announced that they have ... RXi,s novel and proprietary sd-rxRNA® technology for ... The collaboration has the potential to result ... cancer treatments that could be a significant ...
(Date:3/27/2015)... YORK , March 27, 2015  Delcath ... pharmaceutical and medical device company focused on oncology ... and metastatic liver cancers, announces the reporting of ... Company,s Melphalan Hydrochloride for Injection with the Delcath ... a poster presentation at the Society of Surgical ...
Breaking Medicine Technology:InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5
Cached News: